[go: up one dir, main page]

PL2117571T3 - Epitop receptora aktywatora plazminogenu typu urokinazy - Google Patents

Epitop receptora aktywatora plazminogenu typu urokinazy

Info

Publication number
PL2117571T3
PL2117571T3 PL07862653T PL07862653T PL2117571T3 PL 2117571 T3 PL2117571 T3 PL 2117571T3 PL 07862653 T PL07862653 T PL 07862653T PL 07862653 T PL07862653 T PL 07862653T PL 2117571 T3 PL2117571 T3 PL 2117571T3
Authority
PL
Poland
Prior art keywords
urokinase
plasminogen activator
type plasminogen
activator receptor
receptor epitope
Prior art date
Application number
PL07862653T
Other languages
English (en)
Inventor
Graham Parry
Andrew P. Mazar
Original Assignee
Monopar Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monopar Therapeutics Inc. filed Critical Monopar Therapeutics Inc.
Publication of PL2117571T3 publication Critical patent/PL2117571T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL07862653T 2006-12-08 2007-12-07 Epitop receptora aktywatora plazminogenu typu urokinazy PL2117571T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87362706P 2006-12-08 2006-12-08
US93003407P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
PL2117571T3 true PL2117571T3 (pl) 2017-08-31

Family

ID=39512272

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07862653T PL2117571T3 (pl) 2006-12-08 2007-12-07 Epitop receptora aktywatora plazminogenu typu urokinazy

Country Status (9)

Country Link
US (1) US8105602B2 (pl)
EP (1) EP2117571B1 (pl)
JP (2) JP2010512324A (pl)
CA (1) CA2671971C (pl)
DK (1) DK2117571T3 (pl)
ES (1) ES2636451T3 (pl)
PL (1) PL2117571T3 (pl)
PT (1) PT2117571T (pl)
WO (1) WO2008073312A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4890449B2 (ja) * 2004-05-25 2012-03-07 アテニュオン， エルエルシー 下流ｕＰＡＲ相互作用を阻害するウロキナーゼ型プラスミノーゲン活性化因子（ｕＰＡ）とそのレセプター（ｕＰＡＲ）との複合体に結合するリガンド：診断または治療における同定および使用
PL2117571T3 (pl) 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
NZ600470A (en) * 2009-12-09 2015-02-27 Bayer Pharma AG Anti-c4.4a antibodies and uses thereof
EP2534179A4 (en) * 2010-02-12 2013-07-17 Univ California UPAR BINDING AGENT AND METHOD FOR THEIR USE
US20130280162A1 (en) * 2010-12-22 2013-10-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare uPAR-ANTAGONISTS AND USES THEREOF
JP2014529581A (ja) 2011-08-05 2014-11-13 イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ 構成的に活性なｕＰＡＲバリアントならびに阻害抗体の生成および単離へのそれの使用
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
ES2744175T3 (es) * 2013-08-01 2020-02-24 Massachusetts Gen Hospital Biomarcadores suPAR no glucosilados y usos de los mismos
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2016324479B2 (en) 2015-09-18 2022-12-01 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
EP4165070A4 (en) * 2020-06-15 2025-04-02 Monopar Therapeutics Inc. PRECISION RADIOMUNOTHERAPY TARGETING OF THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR) FOR THE TREATMENT OF SEVERE COVID-19
EP4341265A4 (en) * 2021-05-21 2025-07-23 Northstar Medical Tech Llc TRIVALENT RADIOISTOPE BIO-TARGETED RADIOPHARMACEUTICAL, METHODS OF PREPARATION AND USE
CN116410312A (zh) * 2021-12-29 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型upar单域抗体的开发
JP2025510581A (ja) * 2022-03-07 2025-04-15 ラッシュ ユニバーシティ メディカル センター タンパク質分解性ｕＰＡＲタンパク質であるＤ２Ｄ３の阻害による糖尿病および腎臓疾患の新規処置
CN117264061B (zh) * 2023-11-22 2024-03-01 中山大学附属第八医院（深圳福田） 一种识别uPAR的纳米抗体及其应用
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8721023D0 (en) 1987-09-07 1987-10-14 Lepetit Spa Modified plasminogen activators
IT1228881B (it) 1988-08-12 1991-07-09 Lepetit Spa Anticorpo monoclonale specifico per l'epitopo dell'urochinasi prourichinasi corrispondente alla regione denominata gfd
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
EP1013285A3 (en) 1989-04-07 2004-05-19 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Urokinase-type plasminogen activator receptor
US5519120A (en) 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
US5891664A (en) 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
EP0574391B1 (en) 1990-10-18 2002-06-26 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Antibodies against the urokinase receptor and their use
US5561220A (en) 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
CA2123874A1 (en) 1991-11-18 1993-05-27 Ikuko F. Mizukami Methods for detecting and isolating upa-r and inhibiting the binding of upa to upa-r
US5556609A (en) 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
ATE190501T1 (de) 1992-05-28 2000-04-15 Univ Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO1995004281A1 (en) 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
US5532132A (en) 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US5618513A (en) 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
MXPA00004256A (es) 1997-11-03 2005-07-01 Human Genome Sciences Inc Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor.
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
CA2366514C (en) 1999-04-13 2009-09-15 Manfred Schmitt Diagnostic and therapeutic use of antibodies against the urokinase receptor
DE60219888T2 (de) 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
US6846484B2 (en) 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
ATE524739T1 (de) 2002-02-13 2011-09-15 American Diagnostica Inc Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten
AU2003216512A1 (en) 2002-03-18 2003-10-08 Dyax Corporation Integrin ligand
KR100470535B1 (ko) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
WO2004099780A1 (en) 2003-05-06 2004-11-18 Rigshospitalet Immunoassays for the detection of urokinase receptor forms
KR20060130588A (ko) 2003-11-18 2006-12-19 아테뉴온, 엘엘씨 우로키나제의 아미노 말단 단편에 결합하는 항체 및/또는이의 접합체, 조성물 및 이의 용도
US7541159B2 (en) 2004-04-14 2009-06-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Molecular-specific urokinase antibodies
JP4890449B2 (ja) * 2004-05-25 2012-03-07 アテニュオン， エルエルシー 下流ｕＰＡＲ相互作用を阻害するウロキナーゼ型プラスミノーゲン活性化因子（ｕＰＡ）とそのレセプター（ｕＰＡＲ）との複合体に結合するリガンド：診断または治療における同定および使用
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
PL2117571T3 (pl) 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy

Also Published As

Publication number Publication date
CA2671971A1 (en) 2008-06-19
US8105602B2 (en) 2012-01-31
EP2117571A4 (en) 2010-08-04
JP2014224134A (ja) 2014-12-04
ES2636451T3 (es) 2017-10-05
US20080199476A1 (en) 2008-08-21
PT2117571T (pt) 2017-06-14
EP2117571B1 (en) 2017-03-08
JP6019457B2 (ja) 2016-11-02
WO2008073312A2 (en) 2008-06-19
EP2117571A2 (en) 2009-11-18
JP2010512324A (ja) 2010-04-22
WO2008073312A3 (en) 2008-10-30
WO2008073312B1 (en) 2008-12-18
DK2117571T3 (en) 2017-05-08
CA2671971C (en) 2021-03-30

Similar Documents

Publication Publication Date Title
PT2117571T (pt) Resumo
GB2436451B (en) Dynamic vibrational control
GB2436905B (en) Vibrator
GB2438255B (en) Vibrator
GB0614947D0 (en) Epitope reduction therapy
IL192980A0 (en) Super soft foams
GB0700345D0 (en) Vibrator
ZA201003730B (en) Recombinantly modified plasmin
AU313434S (en) Chair
GB0903663D0 (en) Thermoacoustic device
EP1960900A4 (en) COMPLEMENTARY GRAPHIC PIPELINE
IL196619A0 (en) Liner
GB0623813D0 (en) Foam reduction
GB2426308B (en) Joint for plumbing
TWM299715U (en) Cushion structure for packing
GB0604439D0 (en) Liner for furniture
GB0519824D0 (en) Absorbent liner for carry or chair
GB0500270D0 (en) Pipeline construction
ZA200701700B (en) Cushion
GB0807332D0 (en) Tracj bed structures
GB0609094D0 (en) Steel set chair
AU307800S (en) Chair
AU311778S (en) Chair
AU307799S (en) Chair
AU307801S (en) Chair